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Materials and instrumentation. Unless otherwise specified, chemicals were purchased from commercially available sources and used without further purification. The E. coli A-site (5'-GGCGUCACACCUUCGGGUAAGUCGCC-3') and human A-site (5'-GGCGUCGCUACUUCGGUAAAAGUCGCC-3') models with a 2' ACE protecting group were purchased from Thermo Scientific Dharmacon. RNA oligomers were deprotected according to the manufacturer's protocol, and the deprotection buffer was removed by evaporation using SpeedVac (GeneVac). All oligomers were resuspended in buffer prepared in DEPC-treated H 2 O (OmniPure) and their concentrations were determined by NanoQuant Plate (Infinite M1000 Pro, Tecan) using absorption coefficients at 260 nm provided by the manufacturer. Neomycin B (NEO, Fisher), F-NEO, and compounds 6-16 were dissolved in DEPC-treated H 2 O (OmniPure or Fisher) to desired concentrations. F-NEO was synthesized and purified as described before.
1 F-NEO concentration was checked by absorbance at 485 nm (ε 485 nm = 13,260 M -1 cm -1 ). 1 H and 13 C NMR spectra were recorded on a JEOL (Tokyo, Japan) ECA 500 MHz FT-NMR spectrometer,
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Bruker Avance-300 spectrometer, or Bruker Avance-500 spectrometer. Mass spectra (MALDI-TOF) were recorded using a Bruker Daltonics/Omniflex MALDI-TOF spectrometer. Chemistry: Experimental procedures for the preparation of compounds 2-15 and their characterization (Fig. S1 ). 
Preparation of ethyl 3,5-dibromobenzoate (2).
The known compound 2 was synthesized following a previously published procedure with slight modifications (Fig. 1) .
2 98% sulfuric acid (1.0 mL) was added to a suspension of 3,5- 
Preparation
of ethyl 3,5-bis(3-hydroxy-3-methylbut-1-yn-1-yl)benzoate (3). The known compound 3 was synthesized following a previously published procedure with slight modifications (Fig. 1) .
2, 3 A mixture of ethyl 3,5-dibromobenzoate (2) (0.15 g, 0.50 mmol), 2-methylbut-3-yn-2-ol (0.13 g, 1.5 mmol), THF (3.0 mL), and Et 3 N (3.0 mL) was stirred under Ar for 30 min. Pd(PPh 3 ) 2 Cl 2 (17 mg, 0.025 mmol) and CuI (9.5 mg, 0.05 mmol) were then added to the solution. The reaction mixture was stirred for 15 h at 80 °C. 
Preparation of 3,5-Diethynylbenzoic acid (4).
The known compound 4 was synthesized following a previously published procedure with slight modifications (Fig. 1) .
2, 3 A mixture of ethyl 3,5-bis(3-hydroxy-3-methylbut-1-yn-1-yl)benzoate (3) (0.31 g, 1.0 mmol), KOH (0.34 g, 6.0 mmol), and i-PrOH (5.0 mL) was stirred for 4 h at 90 °C. After cooling to room temperature, the reaction mixture was acidified to pH 2 by using 1 M HCl, and then was extracted trice with EtOAc. The EtOAc layer was washed with H 2 O. The solvent was then removed and the residual solid was purified by column chromatography (SiO 2 , CH 2 Cl 2 :EtOAc:AcOH/250:50:1) to afford the desired compound 4 (100 mg, 59%) as white solid:
1 H NMR (500 MHz, CDCl 3 ) δ 8.21 (d, J = 1.5 Hz, 2H), 7.85 (t, J = 1.5 Hz, 1H), 3.19 (s, 2H).
Preparation of Boc-protected NEO dimer (5).
A mixture of NEO sulfate (9.09 g, 10.0 mmol), Na 2 CO 3 (13.78 g, 130.0 mmol), di-tert-butyl dicarbonate (28.37 g, 130.0 mmol), H 2 O (480 mL), and MeOH (480 mL) was stirred at room temperature for 3 h. After removal of 500 mL of the solvent under reduced pressure, the solid was collected by filtration and washed with H 2 O. The solid was then dried and purified by a column chromatography (SiO 2 , EtOAc:hexane:iPrOH/90:30:3) to afford 1,3,2',6',2'",6'"-hexa-N-(tert-butoxycarbonyl)-NEO (7.41 g, 61%) as a white solid. A portion of this purified compound (4.86 g, 4.0 mmol) was dissolved in dry pyridine (40 mL) and 2,4,6-triisopropylbenzenesulfonyl chloride (TPSCl) (9.69 g, 32.0 mmol) was added. The reaction mixture was stirred at room temperature for 41 h prior to being neutralized with saturated NaHCO 3 (Fig. 1) , which was characterized after the removal of the Boc protecting group (compound 6) (Fig. S1 ).
Preparation of compound 6 (DPA939)
by Boc deprotection. Boc-protected NEO dimer 5 (37.1 mg, 0.014 mmol) was dissolved in a solution of TFA:H 2 O/9:1 (0.7 mL). The reaction mixture was stirred at room temperature for 2 h. The solution was then poured into ice-cooled Et 2 O (10 mL). The resulting precipitate was washed with Et 2 O (twice) to afford the desired compound 6 (36.3 mg, 92%) as a white solid ( 
General procedure for the synthesis of L-arginine NEO dimer conjugates 7-15 (Fig. S1B).
Step 1: Swelling of the resin (two times): Add 1.0 mL of DMF and rink amide MBHA resin (16) (100-200 mesh, loading 0.59 mmol/g) (13.6 mg, 0.008 mmol) to a 3 mL polypropylene cartridge with one polyethylene frit, stir for 1 min, and drain the solvent.
Step 2: Deprotection of the resin (two times): Add 0.4 mL of 25% (v/v) piperidine in NMP, stir for 1-2 min, and drain the solvent.
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Step 3: Washing of the deprotected resin (four times): Add 0.4 mL of NMP to the resin, stirred for 5 s, and drain the solvent. This step generates resin 17.
Step 4 After complete assembly and prior to cleavage of the product from the resin (Step 5 below), perform a final wash of the resin with CH 2 Cl 2 four times and then air-dry the resin for over 1 h.
Step 5: Cleavage of the product from the resin: Add 0.4 mL of cleavage solution (TFA:phenol:H 2 O:TIPS/88:5:5:2) to the resin and stir gently for 2 h at rt. After filtration, wash the resin with 0.4 mL of TFA:H 2 O/9:1. Add dropwise the filtrate to ice-cooled Et 2 O (10 mL) to precipitate the desired product. Wash the solid with Et 2 O (twice).
Step 6: Final purification: To a mixture of the desired product obtained in Step 5, add Boc 2 O (33 mg, 0.15 mmol), Na 2 CO 3 (16 mg, 0.15 mmol), MeOH (0.3 mL), and H 2 O (0.3 mL), and stir for 4 h at rt. After adding additional H 2 O (10 mL) and centrifuging, wash the precipitate with H 2 O (2x 1 mL), then with Et 2 O (4x 1 mL). After air drying the washed solid, dissolve it in TFA:H 2 O/9:1 (0.4 mL) and stir at rt for 2 h. Add Et 2 O (10 mL) to the above solution to re-precipitate the final product and wash it with Et 2 O (2x 1 mL). (Fig. 1C) were initially screened using an F-NEO competitive binding assay as previously described 4 with few modifications. Each compound at 0.1 µM concentration was added to 0.1 µM F-NEO:A-site complex to a final volume of 200 µL. The displacement of F-NEO by test compounds was measured by an increase of emission relatively to F-NEO:A-site complex alone (ΔF). The percentage of displacement was calculated using equation 1 relatively to the fluorescence of 0.1 µM F-NEO (ΔF F-NEO ):
Characterization of L-
IC 50 measurements. IC 50 values for compounds 6-15 were determined by titrations of F-NEO-A-site complex at 0.1 µM concentrations with increasing concentrations of tested compounds ranging from 0.002 µM to 2.0 µM. All titrations were performed in a black 96-well roundbottom plate (Greiner). Emission intensity was measured using 25 reads/well with an Infinite M1000 Pro (Tecan) plate reader (λ ex/em = 485/535 nm). All experiments were performed at least in duplicates using 10 mM HEPES, 50 mM NaCl, and 0.4 mM EDTA at pH 7.0. Graphs for the determination of IC 50 values against E. coli and human are presented in Figs. S24 and S25, respectively.
Determination of selectivity factors. This calculation is intended for a quick and convenient estimation of binding preferences of a compound (cpd) to one A-site versus another. We conduct an exchange reaction between A-site -F-NEO complex and a compound with binding constant K E. coli for E. coli A-site and K human for human A-site:
The following relationship is true:
are dissociation constants between F-NEO and E. coli and human A-sites, respectively, and K d cpd (E. coli) and K d cpd (human) are dissociation constants between a compound and E. coli and human A-sites, respectively. After regrouping:
Measurement of K E. coli and K human is not possible under our experimental conditions (for example, utilized concentrations, signal detection etc), therefore we substitute K with conveniently measured IC 50 , a total concentration of compound or NEO, at which the emission intensity at half of the maximum value is observed. Higher IC 50 value corresponds to a lower binding affinity when IC 50 values for the same A-site are considered. After substitution of the ratio K E.
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coli /K human by IC 50 (human)/IC 50 (E. coli), we can calculate selectivity factor representing the approximation of the binding preference of a compound to E. coli over human A-site:
Determination of MIC values for compounds 6-15. B. cereus ATCC 11778, S. epidermidis ATCC 12228, S. aureus ATCC 25923 were purchased from ATCC (Manassas, VA, USA). Compounds 6-15 and NEO were serially diluted 2-fold to make 50 µM to 0.098 µM final concentrations. Bacterial strains were grown in LB for 24 h (250 rpm, 37 °C). Overnight bacterial culture was diluted to 1:1000, grown for 4 h, diluted again 1:1000, and added to the microplates. Plates were incubated at 37 °C for 16-20 h and inspected visually and with MTT (50 µL of 1 mg/mL).
Determination of aminoglycoside-modifying enzymes (AMEs) activity on compounds 6-15.
The N-acetylation and O-phosphorylation of compounds 6-15 by AMEs was examined as previously described. [5] [6] [7] All reactions were monitored at 37 °C (AAC(6')-Ie/APH(2")-Ia only) or 25 °C on a SpectraMax M5 microplate reader and performed in triplicate. All rates were normalized to that of NEO. All acetylation reactions were monitored using Ellman's method at 412 nm (ε = 14,150 M -1 cm -1 ) using 2 mM DTNB, 150 µM AcCoA (except for Eis where 500 µM was used), 50 mM of the appropriate buffer (except for AAC(2')-Ic where 100 mM was used), 100 µM compounds 6-15, and 0.125 µM (AAC(2')-Ic and AAC(3)-IV) or 0.5 µM (all other AACs) enzyme. Phosphorylation using NADH (0.5 mg/mL) in re-generation of GTP was monitored at 324 nm (ε = 6,220 M -1 cm -1 ). Reactions contained 1 µM APH(2")-Ia or APH(3')-Ia, 2 mM GTP, and 100 µM compounds 6-15. Docking of dimer 11 with RNA A-sites. The 3D structure of compound 11 was obtained using ChemDraw 12.0. Atomic coordinates of the receptor for the docking with the E. coli RNA A-site as well as the human RNA A-site have been extracted from the crystal structures from PDB ID 2A04 8 and 2FQN, 9 respectively. The structure of compound 11 and the receptors were prepared for docking using AutoDock Tools Suite version 1.3.2.
10 All structures were viewed in UCSF Chimera 11 and then brought to their energetically minimized structures by Gaussian utilizing a conjugate gradient method with a 6-31G MP2 force field. AutoDock Tools (ADT) were used to merge nonpolar hydrogen atoms of both RNAs and assign atomic charges. Nonpolar hydrogen atoms of each compound were merged and rotatable bonds were assigned. Grid maps were generated for each atom type using AUTOGRID. An active site box of 70 × 70 × 70 Å 3 with grid spacing of 0.375 Å was created and placed at the center of RNA structures. Docking calculations were carried out using Lamarckian genetic algorithm. A population of random individuals (population size: 150) was used with 2,500,000 energy evaluations. A maximum number of 27,000 generations with mutation rate of 0.02 were used. Fifty independent runs for each compound were performed with each RNA A-site. The resulting positions were clustered according to a root-mean-square criterion of 0.5 Å. 
